Big Law

Biotech deal gets pulses racing

Arnold Bloch Leibler and King & Wood Mallesons have negotiated a major share purchase in an Australian biopharmaceutical provider by Celgene Corporation.

May 06, 2015 • By Digital

Firms: Arnold Bloch Leibler (Mesoblast), Wilson Sonsini Goodrich & Rosati (Mesoblast), King & Wood Mallesons (Celgene), Dechert LLP (Celgene)

Deal: Celgene agreed to purchase 15.3 million ordinary shares in Mesoblast Ltd

Value: A$58.5 million

Area: Capital markets

Key players: ABL commercial partner Andrew Silberberg (pictured) worked on the negotiation alongside senior associate John Kim. Strategic support was provided by managing partner Henry Lanzer and commercial partner Jonathan Wenig.

Deal significance:

This content is available exclusively to Lawyers Weekly premium members.

INDIVIDUAL

Yearly

$ 49.00

per year

SUBSCRIBE NOW

INDIVIDUAL

Monthly

$ 5.00

per month

SUBSCRIBE NOW

Learn more about Premium Benefits and other offers

Username or Email

Password Forgot password?

Keep me signed in on this device.

The investment by Celgene will inject $58.5 million into Australian-owned Mesoblast Ltd.

Celgene is a biotechnology provider based in the United States, described by Arnold Bloch Leibler partner Andrew Silberberg as “a global leader in regenerative medicine”.

Mesoblast is an ASX-listed firm specialising in the treatment of cardiovascular, inflammatory and oncology conditions.

The deal will allow Celgene to strengthen its development and commercialisation pipeline, according to a statement from Arnold Bloch Leibler.

VIEW ALL

“This is another great example of international interest in an innovative Australian company,” Mr Silberberg said.

We're evolving — and so should your insights. Heads up — Lawyers Weekly is going premium from 1 May for just $5 a month. Stay informed without missing a beat. More information coming soon.